FS KKR Capital Corp. Announces First Quarter 2026 Results and Strategic Value Enhancement Actions; Declares Second Quarter 2026 Distribution of $0.42 per share

FS KKR Capital reported Q1 2026 net investment income of $0.42 per share versus $0.48 last quarter, while net asset value fell to $18.83 from $20.89 and earnings per share worsened to $(1.57) from $(0.41). The company also announced a $0.42 quarterly distribution, a $150 million preferred stock investment, a $150 million tender offer at $11 per share, and a $300 million buyback authorization. Net debt-to-equity rose to 131% from 122%, and non-accruals increased to 4.2% of fair value from 3.4%.

Analysis

The package is less a clean capital-return story than a recapitalization plus optics reset. The preferred injection and fee waiver temporarily shore up distributable cash flow, but the real signal is that management is choosing financial engineering over organic balance-sheet repair: leverage is still elevated, non-accruals are rising, and the asset-marking problem is not solved by buybacks. That matters because a BDC at this leverage profile can look stable on NII while equity value continues to erode if credit marks keep slipping.

The tender plus repurchase authorization creates an unusual setup where the sponsor is effectively providing liquidity to itself while establishing a valuation floor below NAV. In the near term, that should tighten the discount and support the shares mechanically, but it also reduces flexibility: if repurchases soak up cash while originations slow, FSK may be forced to choose between defending the dividend and defending the balance sheet later this year. The most important second-order effect is that the market will likely start capitalizing FSK more like a self-liquidating credit vehicle than a growing BDC unless underlying portfolio marks stabilize.

KKR is the quieter winner here. The actions burnish platform confidence, protect the listed affiliate from a disorderly de-rating, and preserve longer-dated AUM/funding economics even if short-term dilution from fee waivers and capital support is real. The contrarian risk is that the announced support is read as a pre-emptive admission that the common is under-earning its distribution and that NAV could still reset lower over the next 1-2 quarters if spread widening persists.

For the next 30-90 days, the trade is probably tighter in the stock than in the credit: the equity can rally on tender mechanics, but the downside convexity remains if asset marks continue to deteriorate. The more durable signal will be whether the repurchase program is used aggressively only after the tender clears, or whether management preserves dry powder because underwriting conditions are still weakening.

Key Decisions for Investors

• Long FSK common against a short position in a diversified BDC basket for the next 4-8 weeks: trade the tender/repurchase floor while isolating idiosyncratic credit-mark risk; stop if NAV erosion accelerates in the next quarter.
• After the tender window closes, fade strength in FSK with put spreads 1-3 months out if the stock approaches the tender price and volume dries up; risk/reward improves if repurchases prove slower than announced.
• Prefer KKR over FSK on a 3-6 month horizon: the market should reward platform-level resilience while assigning the mark-to-market pain to the listed affiliate; use KKR/FSK relative long-short if you want to express that split.
• Avoid chasing FSK for yield until after the next quarter: the fee waiver and preferred capital improve coverage only temporarily, so a high dividend support story here is weaker than it appears.
• If FSK trades materially above the tender price before closing, consider a tactical short against NAV-degradation risk; upside is capped by the financing mechanics, while downside re-opens if credit metrics worsen.